What disease does Bortezomib treat?

Bortezomib (Bortezomib) is an important anticancer drug mainly used to treat specific types of hematological malignancies. It is approved for the treatment of the following major conditions:

1.Multiple Myeloma (Multiple Myeloma): Multiple myeloma is a malignant tumor whose main feature is the abnormal proliferation of plasma cells in the bone marrow. These abnormal cells form lesions in the bones, causing bone pain, fractures, anemia and a compromised immune system. Bortezomib inhibits the proliferation of multiple myeloma cells and reduces protein degradation, thereby improving patients' symptoms, prolonging survival, and improving quality of life.

2.Certain non-Hodgkin lymphomas (Non-Hodgkin Lymphoma): Bortezomib is also used to treat certain non-Hodgkin lymphomas, a malignant tumor of the lymphatic system in which lymphocytes proliferate abnormally. It can be used as a monotherapy or in combination with other drugs, depending on the type and severity of the disease, to help control tumor growth.

As a targeted therapy, Bortezomib achieves precise treatment by targeting specific proteasomes in cancer cells, reducing the uncomfortable impact on healthy cells. Compared with traditional broad-spectrum chemotherapy drugs, Bortezomib has lower toxicity. This makes it an important drug option for the treatment of hematological malignancies such as multiple myeloma and certain non-Hodgkin lymphomas, providing patients with better treatment prospects and chances of survival. At the same time, the success of bortezomib has also inspired continuous research and innovation in the field of cancer treatment, paving the way for future anti-cancer drug development.

Bortezomib is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of around 3,000 to 4,000 yuan. Please consult the local hospital pharmacy for specific prices and reimbursement policies. The cheaper ones abroad are mainly Indian generic drugs, which cost around 1,000 yuan and have basically the same ingredients as the domestic bortezomib drug.